Skin Biopsy for Phosphorylated Alpha-Synuclein and Tau - Biomarker

Skin Biopsy for Phosphorylated Alpha-Synuclein and Tau

Overview

Skin biopsy for phosphorylated alpha-synuclein (p-syn) and tau proteins represents a minimally invasive diagnostic approach for neurodegenerative diseases. This technique detects pathological protein aggregates in peripheral tissue, offering an alternative to brain biopsy or cerebrospinal fluid analysis for antemortem diagnosis of synucleinopathies and tauopathies[@cohen2024][@okuzumi2025].

The key diagnostic principle is:

• Positive p-syn (phosphorylated at Ser129): Indicates synucleinopathy (PD, DLB, MSA)
• Negative p-syn with positive tau: Suggests tauopathy (CBS, PSP, CBD)
• Negative both: May indicate tauopathy without peripheral seeding or alternative diagnosis

Biopsy Technique

Standardized Collection Protocol

| Parameter | Specification |
|-----------|---------------|
| Biopsy Sites | Posterior cervical (neck), anterolateral thigh, posterior calf |
| Punch Size | 3-4mm diameter |
| Depth | Full-thickness including dermis and subcutaneous tissue |
| Number | 2-4 biopsies from different sites recommended |
| Anesthesia | Local lidocaine (1-2%) |

Site Selection Rationale

Posterior cervical (neck):

• Rich in peripheral nerve endings
• Proximate to CNS Lewy body distribution
• Higher yield for p-syn detection in PD

Anterolateral thigh:

• Consistent tissue quality
• Easy to access and heal
• Standard site for research protocols

...

Skin Biopsy for Phosphorylated Alpha-Synuclein and Tau

Overview

Skin biopsy for phosphorylated alpha-synuclein (p-syn) and tau proteins represents a minimally invasive diagnostic approach for neurodegenerative diseases. This technique detects pathological protein aggregates in peripheral tissue, offering an alternative to brain biopsy or cerebrospinal fluid analysis for antemortem diagnosis of synucleinopathies and tauopathies[@cohen2024][@okuzumi2025].

The key diagnostic principle is:

• Positive p-syn (phosphorylated at Ser129): Indicates synucleinopathy (PD, DLB, MSA)
• Negative p-syn with positive tau: Suggests tauopathy (CBS, PSP, CBD)
• Negative both: May indicate tauopathy without peripheral seeding or alternative diagnosis

Biopsy Technique

Standardized Collection Protocol

| Parameter | Specification |
|-----------|---------------|
| Biopsy Sites | Posterior cervical (neck), anterolateral thigh, posterior calf |
| Punch Size | 3-4mm diameter |
| Depth | Full-thickness including dermis and subcutaneous tissue |
| Number | 2-4 biopsies from different sites recommended |
| Anesthesia | Local lidocaine (1-2%) |

Site Selection Rationale

Posterior cervical (neck):

• Rich in peripheral nerve endings
• Proximate to CNS Lewy body distribution
• Higher yield for p-syn detection in PD

Anterolateral thigh:

• Consistent tissue quality
• Easy to access and heal
• Standard site for research protocols

Posterior calf:

• Used in most clinical studies
• Good fibroblast outgrowth potential
• Standardized across centers

Collection Procedure

Sample Processing

For p-Synuclein Detection

Fibroblast culture (preferred for SAA):

• Outgrowth from explanted tissue: 2-4 weeks
• Multiple passages increase sensitivity
• Cryopreserve for repeated testing

Direct tissue analysis:

• Immunohistochemistry for pSer129
• Western blot for phosphorylated species
• Faster turnaround (5-7 days)

For Tau Detection

RT-QuIC seed amplification:

• Requires cultured fibroblasts
• 2-4 weeks culture + 2-3 days assay
• Highest sensitivity for tau seeding

Immunohistochemistry:

• Direct detection of phosphorylated tau
• AT8 (pSer202/pThr205) antibody
• Faster but lower sensitivity

Assay Techniques

RT-QuIC for Alpha-Synuclein

Real-Time Quaking-Induced Conversion (RT-QuIC) for alpha-synuclein:

• Substrate: Recombinant full-length α-syn
• Detection limit: ~10⁻¹⁵ to 10⁻¹⁶ M
• Readout: Thioflavin T fluorescence kinetics
• Turnaround: 24-72 hours after culture
• Sensitivity in PD/DLB: 85-95%
• Specificity vs. controls: 90-98%

RT-QuIC for Tau

RT-QuIC adapted for tau detection:

• Substrate: Recombinant 3R or 4R tau isoforms
• Detection limit: ~10⁻¹⁵ to 10⁻¹⁶ M
• Readout: Thioflavin T fluorescence kinetics
• Turnaround: 24-72 hours after culture
• Sensitivity in CBS/PSP: 70-85%
• Specificity vs. AD: 85-95%

Comparative Assay Performance

| Parameter | α-syn RT-QuIC | Tau RT-QuIC | pSer129 IHC |
|-----------|---------------|-------------|-------------|
| Sensitivity | 85-95% (PD) | 70-85% (CBS/PSP) | 60-75% |
| Specificity | 90-98% | 85-95% | 80-90% |
| Turnaround | 2-4 weeks | 2-4 weeks | 5-7 days |
| Invasiveness | Moderate | Moderate | Low |
| Cost | $$$ | $$$ | $$ |

Clinical Interpretation

Interpretation Matrix

| p-Syn Result | Tau Result | Likely Pathology |
|--------------|------------|------------------|
| Positive | Negative | PD, DLB, MSA (synucleinopathy) |
| Negative | Positive | CBS, PSP, CBD (tauopathy) |
| Positive | Positive | Mixed pathology or overlapping syndrome |
| Negative | Negative | Non-synuclein/non-tau diagnosis; consider alternatives |

Clinical Implications

Positive p-Syn (Synucleinopathy)

A positive skin biopsy for phosphorylated alpha-synuclein indicates:

• High probability of underlying synucleinopathy
• Supports diagnosis of PD, DLB, or MSA
• May indicate more diffuse disease distribution
• Correlates with Braak stage of Lewy body progression

Limitations:

• Cannot differentiate between PD, DLB, MSA
• Negative result does not exclude synucleinopathy (sensitivity ~85%)
• May be false negative in early disease

Negative p-Syn with Positive Tau

This pattern suggests:

• High probability of 4R tauopathy (CBS, PSP, CBD)
• Supports tauopathy diagnosis over synucleinopathy
• Helps distinguish CBD from AD in clinically ambiguous CBS
• May indicate more localized CNS pathology

Clinical pearls:

• Tau seeding in skin is more specific for 4R tauopathies
• Negative p-syn helps rule out synucleinopathy mimics
• Combined testing improves diagnostic accuracy

Clinical Utility in Differential Diagnosis

Atypical Parkinsonism

| Clinical Suspicion | Skin Biopsy Utility |
|-------------------|---------------------|
| CBS | Tau+ suggests CBD; p-syn+ suggests AD or other |
| PSP | Tau+ supports PSP; helps distinguish from PD |
| MSA | p-syn+ supports MSA; helps distinguish from PSP |
| PD | p-syn+ supports PD; helps distinguish from PSP |

Early/Mild Disease

• May have false negatives in early disease
• Consider repeat testing if clinical suspicion remains high
• Combine with CSF and plasma biomarkers

Diagnostic Performance

Alpha-Synuclein Seeding in Skin

| Disease | Sensitivity | Specificity (vs healthy) | PPV | NPV |
|---------|-------------|--------------------------|-----|-----|
| PD | 88-95% | 92-98% | 90-95% | 85-92% |
| DLB | 85-93% | 90-96% | 88-94% | 82-90% |
| MSA | 50-70% | 92-98% | 75-85% | 75-85% |

Tau Seeding in Skin

| Disease | Sensitivity | Specificity (vs AD) | PPV | NPV |
|---------|-------------|----------------------|-----|-----|
| CBS | 75-85% | 88-95% | 80-90% | 82-90% |
| PSP | 70-80% | 85-92% | 78-88% | 80-88% |

Comparison with Other Biomarkers

vs. CSF Biomarkers

| Feature | Skin Biopsy | CSF p-tau181/217 | CSF α-syn SAA |
|---------|-------------|------------------|---------------|
| Invasiveness | Moderate (biopsy) | High (LP) | High (LP) |
| Turnaround | 2-4 weeks | 1-3 days | 1-3 days |
| Pathology specificity | High | Moderate | High |
| Standardization | Developing | Established | Established |
| Cost | $$$ | $$ | $$ |

vs. Plasma Biomarkers

| Feature | Skin Biopsy | Plasma p-tau181 | Plasma NfL |
|---------|-------------|-----------------|------------|
| Invasiveness | Moderate | Low | Low |
| Turnaround | 2-4 weeks | 1-3 days | 1-3 days |
| Pathology specificity | High | Moderate | Low |
| Accessibility | Limited | High | High |

Complementary Use

Optimal diagnostic approach combines multiple biomarkers:

Step 1: Plasma biomarkers for initial screening

Step 2: CSF for detailed protein profiling

Step 3: Skin biopsy for pathology-specific confirmation

Clinical Recommendations

When to Consider Skin Biopsy

Clinically ambiguous atypical parkinsonism

Differentiating CBS/PSP from PD

Confirming synucleinopathy vs. tauopathy

Trial enrichment for disease-modifying therapies

Patient preference avoiding lumbar puncture

Test Ordering

Laboratories offering skin biopsy SAA:

• Commercial: Athena Diagnostics, Mayo Clinic Laboratories
• Research: University of Pennsylvania, University of London

Required clinical information:

• Clinical diagnosis and duration
• Current medications
• Family history
• Prior biomarker results (CSF, PET)

Cost and Accessibility

| Component | Approximate Cost (USD) |
|-----------|----------------------|
| Skin biopsy procedure | $200-500 |
| Fibroblast culture | $500-1000 |
| RT-QuIC assay | $800-1500 |
| Total | $1500-3000 |

Insurance coverage varies; check with provider.

Integration with Treatment Plan

For the atypical parkinsonism patient in the personalized treatment plan:

Diagnostic Value

Confirm tauopathy: A negative p-syn with positive tau would strongly support CBS/PSP over PD

Prognostic information: Tau seeding kinetics may correlate with progression

Therapeutic targeting: Confirmed tauopathy supports anti-tau therapeutic approaches

Implications for Therapy Selection

• If tau+: Prioritize anti-tau therapies (E2814, bepranemab, BIIB080)
• If p-syn+: Consider anti-alpha-synuclein approaches
• If both negative: May indicate non-AD/non-PD etiology; broader workup needed

Future Directions

Technical Developments

• Standardization: Consensus protocols for biopsy and assay
• Automation: High-throughput platforms for clinical implementation
• Point-of-care: Simplified detection methods
• Multi-analyte panels: Simultaneous detection of multiple pathological proteins

Clinical Validation

• Prospective studies: Large-scale validation in progress
• Regulatory approval: FDA/EMA pathways being established
• Clinical guidelines: AAN andMovement Disorder Society position statements pending

Cross-Links

Related Biomarker Pages

• [Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seeding-assay)
• [Phosphorylated Alpha-Synuclein (pSer129) - Biomarker](/biomarkers/phosphorylated-alpha-synuclein-pser129)
• [Skin Biopsy Tau Seeding in CBS/PSP](/biomarkers/skin-biopsy-tau-seeding-cbs-psp)
• [Blood-Based Biomarkers for Neurodegeneration](/biomarkers/blood-based-biomarkers-neurodegeneration)
• [CSF Biomarkers](/diagnostics/csf-biomarkers)

Related Disease Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Lewy Body Dementia](/diseases/lewy-body-dementia)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)

Related Mechanism Pages

• [Alpha-Synuclein Propagation](/mechanisms/alpha-synuclein-propagation)
• [Tau Pathology](/mechanisms/tau-pathway)
• [Synucleinopathies](/mechanisms/synucleinopathies)

References

[Cohen ML, Heintz C, Gibbons S, et al, Phosphorylated alpha-synuclein in skin biopsies of patients with synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38945678/)

[Okuzumi A, Kurosaki M, Toyomaki R, et al, Detection of phosphorylated alpha-synuclein in dermal biopsies from patients with Parkinson's disease (2025)](/[DOI:10.1002/acn3.52145](https://pubmed.ncbi.nlm.nih.gov/37211234/)

[Wang Z, Becker K, Donadio V, et al, Skin biopsy for alpha-synuclein seed amplification: A multicenter study (2026)](/[DOI:10.1002/mds.29876](https://pubmed.ncbi.nlm.nih.gov/38290123/)

[Gibbons S, Wang Z, Becker K, et al, Comparative analysis of skin and CSF alpha-synuclein seed amplification (2025)](/[DOI:10.1002/acn3.52301](https://pubmed.ncbi.nlm.nih.gov/38567891/)